The Korean Journal of Internal Medicine

Search

Close

Special Review
Korean J Med. 2014;86(4):399-404. Published online April 1, 2014.
DOI: https://doi.org/10.3904/kjm.2014.86.4.399
비알코올 지방간 질환의 역학
정고은, 김동희
서울대학교병원 강남센터 소화기내과
Epidemiology of Nonalcoholic Fatty Liver Disease
Goh Eun Chung, Donghee Kim
Division of Gastroenterology, Department of Internal Medicine, Healthcare Research Institute, Healthcare System Gangnam Center, Seoul National University Hospital, Seoul, Korea
Corresponding author: Donghee Kim ,Tel: +82-2-2112-5632, Fax: +82-2-2112-5635, Email: messmd@chol.com


߽ɾ :비알코올 지방간 질환; 지방간염; 유병률; 위험인자; 자연 경과
Abstract
Nonalcoholic fatty liver disease (NAFLD) is recognized as the most common liver disease with an estimated prevalence of 20-30% in the Western world and 16-33% in Korea. NAFLD encompasses a broad spectrum of hepatic dysfunction ranging from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma. The increasing prevalence of NAFLD is particularly worrying because patients appear to have higher non-liver-related and liver-related death, as compared to the general population. Given its well-known association with metabolic comorbidities, NAFLD is commonly associated with obesity, type II diabetes, dyslipidemia, and metabolic syndrome. The natural history of NAFLD remains unclear due to its indolent clinical course and the lack of well-designed prospective studies. The prognosis of NAFLD depends on the histological subtype, while NASH may be associated with liver fibrosis and cirrhosis and may progress to hepatocellular carcinoma. The overall and liver-related mortality are increased in patients with NASH, as compared to NAFL and the general population. NAFLD is strongly associated with cardiovascular disease and type 2 diabetes, so it should also be considered a metabolic liver disease. Further long-term studies of the natural course of NAFLD are warranted. (Korean J Med 2014;86:399-404)

Keywords :Nonalcoholic fatty liver disease, Steatohepatitis, Prevalence, Risk factor, Natural history
hanmi ckdpharm. AMGEN
Memo patch yungjin daewoongbio

Go to Top